Iranzo, Alex
Serralheiro, Pedro
Schuller, Jan-Christof
Schlit, Anne-Françoise
Bentz, Jürgen W. G.
Funding for this research was provided by:
UCB Pharma
Article History
First Online: 28 September 2020
Declarations
:
: UCB Pharma.
: Alex Iranzo: Consulting fees and other honoraria from UCB Pharma; Pedro Serralheiro, Jan-Christof Schuller, Anne-Françoise Schlit: Employees of UCB Pharma; Jürgen W.G. Bentz: Employee and shareholder of UCB Pharma.
: Ethics approval was sought and granted as required by the participating countries.
: Not applicable.
: Not applicable.
: Data from non-clinical studies is outside of UCB’s data sharing policy.
: Not applicable.
: Substantial contributions to study conception and design: AI, PS, J-CS, A-FS, and JWGB; contributions to analysis and interpretation of the data: AI, PS, J-CS, A-FS, and JWGB; drafting the article or revising it critically for important intellectual content: AI, PS, J-CS, A-FS, and JWGB; final approval of the version of the article to be published: AI, PS, J-CS, A-FS, and JWGB.
: UCB sponsored the study and the development of the manuscript/publication and reviewed the text to ensure that from a UCB perspective, the data presented in the publication are scientifically, technically, and medically supportable, that they do not contain any information that has the potential to damage the intellectual property of UCB, and that the publication complies with applicable laws, regulations, guidelines and good industry practice. The authors approved the final version to be published after critically revising the manuscript/publication for important intellectual content.